Management of patients with Behcet's disease during theCOVID-19 pandemic

Basit Öğe Kaydı
dc.contributor.authorDursun, Recep
dc.contributor.authorTemiz, Selami A.
dc.contributor.authorOzer, Ilkay
dc.contributor.authorDaye, Munise
dc.contributor.authorAtaseven, Arzu
dc.date.accessioned2024-02-23T14:24:06Z
dc.date.available2024-02-23T14:24:06Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractBehcet's disease is a disease characterized by chronic inflammatory vasculitis. In the clinical symptoms of Behcet's disease, many immunosuppressive and immunomodulatory drugs are used. The suspicion that drugs used in chronic disease treatments such as Behcet's disease during pandemic will increase the risk of transmission of COVID-19 disease, and that the disease may progress more lethally in these patients after the infection caused clinicians to worry. As far as we know, there is no study in the literature about the management of patients with Behcet's disease in the pandemic period. Fifty-four patients with Behcet's disease who were admitted to the dermatology outpatient clinic between 11 March and July 14, 2020 were retrospectively analyzed. In this pandemic period, 44 of 54 patients were recommended to continue their previous treatment. While the dose of medication used by 7 patients was reduced, it was decided to change the treatment of 3 patients. No life-threatening activation was observed. None of the patients developed COVID-19 disease. This article is important in terms of being the first study in the literature examining the treatment of patients with Behcet's disease during the COVID-19. In this period, we know that the treatment practices in chronic diseases change frequently daily, and in this respect, we hope that our study will provide a perspective to other dermatology clinics in terms of the treatment of Behcet's disease during the pandemic.en_US
dc.identifier.doi10.1111/dth.14063
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.issue6en_US
dc.identifier.pmid32710599en_US
dc.identifier.scopus2-s2.0-85089856551en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1111/dth.14063
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13819
dc.identifier.volume33en_US
dc.identifier.wosWOS:000562525300001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofDermatologic Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-Tnf Agentsen_US
dc.subjectAzathioprineen_US
dc.subjectBehcet's Diseaseen_US
dc.subjectColchicineen_US
dc.subjectCovid-19en_US
dc.subjectImmunosuppressive Drugsen_US
dc.titleManagement of patients with Behcet's disease during theCOVID-19 pandemicen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu